Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target…
4 analysts rate AKTS Buy on consensus.
Consensus price target: $32.50 (+93.91% upside from $16.76)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Czibere Akos Chief Medical Officer | Sep 23, 2026 | Sale | 7,401 | $155.65K |
| Czibere Akos Chief Medical Officer | Sep 23, 2026 | Sale | 5,099 | $102.97K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $6.5M | +336.92% | $-63.73M |
| 2024 | $1.49M | -94.57% | $-43.98M |
| 2024 | $27.38M | — | $-167.95M |
Stock data for AKTS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics